LONDON, UK / ACCESSWIRE / December 22, 2017 / Active-Investors.com has just released a free earnings report on NuStar Energy L.P. (NYSE: NS). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=NS . The Company posted its financial results on November 07, 2017, for the third quarter fiscal 2017. The owner and operator of crude oil and refined products pipelines and storage facilities’ earnings before interest, tax, depreciation, and amortization (EBITDA) increased 9.5% on a y-o-y basis. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, NuStar Energy most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=NS

Earnings Highlights and Summary

For three months ended September 30, 2017, NuStar Energy’s total revenues decreased 0.1% to $440.57 million from $441.42 million in Q3 FY16. The Company’s total revenue surpassed analysts’ expectations of $376 million.

During Q3 FY17, NuStar Energy’s gross profit increased 5.7% to $302.49 million from $286.29 million in the same period last year. For the reported quarter, the Company’s gross margin increased 380 basis points to 68.7% of revenue from 64.9% of revenue in Q3 FY16.

For the reported quarter, NuStar Energy’s EBITDA increased 9.5% to $155.77 million from $142.26 million in Q3 FY16. For the reported quarter, the Company’s EBITDA margin increased 320 basis points to 35.4% of revenue from 32.2% of revenue in Q3 FY16.

During Q3 FY17, NuStar Energy’s operating income increased 4.3% to $91.72 million from $87.95 million in the same period last year. For the reported quarter, the Company’s operating margin increased 90 basis points to 20.8% of revenue from 19.9% of revenue in Q3 FY16.

During Q3 FY17, NuStar Energy’s earnings before tax (EBT) decreased 22.4% to $41.34 million from $53.29 million in the same period last year. For the reported quarter, the Company’s EBT margin decreased 270 basis points to 9.4% of revenue from 12.1% of revenue in Q3 FY16.

For the reported quarter, NuStar Energy’s net income decreased 24.5% to $38.59 million from $51.14 million in Q3 FY16. During Q3 FY17, the Company’s diluted EPS decreased 69.4% to $0.15 from $0.49 in the same period last year. Diluted EPS was below analysts’ expectations of $0.27.

NuStar Energy’s Segment Details

Pipeline – During Q3 FY17, the Pipeline segment’s total revenue increased 12.2% to $137.43 million from $122.48 million in the same period last year. For the reported quarter, the segment’s operating income increased 3.7% to $61.12 million from $58.92 million in Q3 FY16. For the reported quarter, the segment’s total throughput volume was 1.21 million barrels per day compared to 920,868 barrels per day in the third quarter of 2016.

Storage – During Q3 FY17, the Storage segment’s total revenue increased 0.2% to $158.07 million from $157.77 million in the same period last year. For the reported quarter, the segment’s operating income increased 1.5% to $59.32 million from $58.42 million in Q3 FY16. The increase was due to higher storage terminal values and lower operating expenses. For the reported quarter, the segment’s total throughput volume was 294,544 barrels per day compared to 810,470 barrels per day in the third quarter of 2016.

Fuels Marketing – During Q3 FY17, the Fuels Marketing segment’s total revenue decreased 11.3% to $147.46 million from $166.19 million in the same period last year. For the reported quarter, the segment’s gross profit decreased 14.7% to $7.35 million from $8.62 million in Q3 FY16. For the reported quarter, the segment’s operating loss was $1.53 million compared to the segment’s operating loss of 337,000 in Q3 FY16.

Balance Sheet

As on September 30, 2017, NuStar Energy’s distributable cash flow decreased 20.2% to $80.19 million from $100.48 million in Q3 FY16. For the reported quarter, the Company’s distributable cash flow available to common limited partners decreased 23.6% to $66.97 million from $87.61 million in Q3 FY16.

Stock Performance Snapshot

December 21, 2017 – At Thursday’s closing bell, NuStar Energy’s stock was marginally down 0.10%, ending the trading session at $29.75.

Volume traded for the day: 302.61 thousand shares.

Stock performance in the last month – up 7.79%

After yesterday’s close, NuStar Energy’s market cap was at $2.80 billion.

Price to Earnings (P/E) ratio was at 78.08.

The stock has a dividend yield of 14.72%.

The stock is part of the Basic Materials sector, categorized under the Oil & Gas Pipelines industry. This sector was up 1.5% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 484840

Stock Monitor: Peak Resorts Post Earnings Reporting

LONDON, UK / ACCESSWIRE / December 22, 2017 / Active-Investors.com has just released a free earnings report on Planet Fitness, Inc. (NYSE: PLNT). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=PLNT. Planet Fitness reported its third quarter fiscal 2017 (Q3 FY17) operating results on November 07, 2017. The fitness center operator outperformed top- and bottom-line expectations and also raised its guidance for the full year 2017. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Peak Resorts, Inc. (NASDAQ: SKIS), which also belongs to the Services sector as the Company Planet Fitness. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=SKIS

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Planet Fitness most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=PLNT

Earnings Highlights and Summary

For its third quarter ended September 30, 2017, Planet Fitness’ total revenue jumped 12.1% to $97.5 million from $87.0 million in Q3 2016. The Company’s revenue numbers exceeded analysts’ estimates of $93.7 million.

Planet Fitness’ same-store sales (comp) were positive for the 43rd consecutive quarter increasing 9.3% on top of a 10% comp gain in Q3 2016.

Planet Fitness’ operating income jumped 29.8% to $34 million for Q3 2017 compared to operating income of $26.2 million in Q3 2016. On an adjusted basis, the Company’s adjusted operating margin was 35.8% in the reported quarter versus 32% in the prior year’s same quarter, an increase of 380 basis points. Planet Fitness’ adjusted EBITDA, jumped 22.4% to $43.4 million from $35.4 million in the prior year’s same period.

During Q3 2017, Planet Fitness’ net income was $18.9 million, or $0.18 per diluted share, compared to net income of $14.9 million, or $0.08 per diluted share, in Q3 2016. The Company’s adjusted net income advanced 17.9% to $18.7 million, or $0.19 per diluted share, from $15.9 million, or $0.16 per diluted share, in the prior year’s same period, and came in ahead of Wall Street’s estimates of $0.16 per share.

Planet Fitness’ Segment Results

During Q3 2017, the franchise segment’s revenue, which includes commission income, surged 30.6% to $35.6 million from $27.2 million in the prior year’s same period. The Company’s corporate-owned stores segment’s revenue advances 7.1% to $28.6 million from $26.7 million in the prior year’s corresponding period.

During Q3 2017, the equipment segment’s revenue grew 0.8% to $33.4 million from $33.1 million in Q3 2016. The Company’s system-wide same store sales increased 9.3%. By segment, franchisee-owned same-store sales increased 9.6% and corporate-owned same-store sales increased 5.1%.

The Franchise segment’s EBITDA surged 31.2% to $29.9 million driven by royalties from new franchised stores opened since September 30, 2016, increased royalty rate and higher same-store sales.

The Company’s corporate-owned stores segment’s EBITDA advanced 14.2% to $12.0 million driven primarily by higher monthly and annual revenue, including an increase in same-store sales, and improved operating margin.

The equipment segment’s EBITDA increased by 7.4% to $7.7 million driven by an increase in replacement equipment sales to existing franchisee-owned stores.

Cash Matters

As of September 30, 2017, Planet Fitness had cash and cash equivalents of $93.3 million compared to cash and cash equivalents of $40.4 million as of December 31, 2016.

Store Update

31 new Planet Fitness franchise stores were opened during Q3 2017, bringing system-wide total stores to 1,432 as of September 30, 2017.

Outlook

For the year ending December 31, 2017, Planet Fitness is forecasting total revenue between $425 million and $430 million. The Company is expecting system-wide same store sales growth in the 9.5% to 10% range, up from its previous guidance of 8% to 9%, and adjusted net income of $79 million to $81 million, or $0.80 to $0.82 per diluted share, compared to the Company’s previous guidance of $0.76 to $0.78. Planet Fitness is anticipating selling and placing equipment into approximately 190 to 200 new stores.

Stock Performance Snapshot

December 21, 2017 – At Thursday’s closing bell, Planet Fitness’ stock advanced 1.61%, ending the trading session at $34.65.

Volume traded for the day: 713.64 thousand shares.

Stock performance in the last month – up 11.34%; previous three-month period – up 28.76%; past twelve-month period – up 72.90%; and year-to-date – up 72.39%

After yesterday’s close, Planet Fitness’ market cap was at $3.29 billion.

Price to Earnings (P/E) ratio was at 52.03.

The stock is part of the Services sector, categorized under the Sporting Activities industry. This sector was up 0.4% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 484841

LONDON, UK / ACCESSWIRE / December 22, 2017 / Active-Investors has a free review on Ituran Location and Control Ltd (NASDAQ: ITRN) (“Ituran”) following the Company’s announcement that it will begin trading ex-dividend on December 26, 2017. To capture the dividend payout, investors must purchase the stock a day prior to the ex-dividend date (excluding weekend) that is by latest at the end of the trading session on December 22, 2017. Active-Investors has initiated due-diligence on this dividend stock. Register with us for more free research including the one on ITRN:

www.active-investors.com/registration-sg/?symbol=ITRN

If your portfolio includes dividend stocks, you have come to the right place for timely information. All you need to do is sign up for your free membership at:

www.active-investors.com/registration-sg

Dividend Declared

On November 15, 2017, Ituran announced that its Board of Directors approved the distribution of a cash dividend in the amount of $0.24 per share, totaling approximately US$5 million. The dividend will be paid to shareholders of record as of December 27, 2017.

Ituran’s indicated dividend represents a yield of 2.84%, which is substantially above the average dividend yield of 1.87% for the Services sector.

Dividend Insights

Ituran has a dividend payout ratio of 44.7%, which indicates that the Company spends approximately $0.45 for dividend distribution out of every $1.00 earned. The dividend payout ratio reflects how much amount a company is returning to shareholders versus how much money it is keeping on hand to reinvest in growth, to pay off debt, and/or to add to its cash reserves.

According to analysts’ estimates, Ituran is forecasted to report earnings of $2.15 per share for the next year, which is substantially above the Company’s annualized dividend of $0.96 per share.

Ituran’s retained earnings as of September 30, 2017, prior to the distribution were US$87.2 million and retained earnings will reach US$82.2 million after the distribution. As of September 30, 2017, the Company had a cash balance in hand of US$31.8 million. As of September 30, 2017, the Company’s current assets (excluding cash, cash equivalents) were US$109.5 million and current liabilities were US$65.5 million. The Company’s strong financial position indicates its ability to absorb any fluctuations in earnings and cash flow and to sustain the dividend distribution for a long period.

About Ituran Location and Control Ltd

Ituran is a leader in the emerging mobility technology field, providing value-added location-based services, including a full suite of services for the connected-car. The Company offers Stolen Vehicle Recovery, fleet management as well as mobile asset location, management & control services for vehicles, cargo and personal security. Its products and applications are used by customers in over 20 countries.

Ituran’s subscriber base has been growing significantly since the Company’s inception to over 1 million subscribers using its location based services with a market leading position in Israel and Brazil. Established in 1995, Ituran has over 1,500 employees worldwide, with offices in Israel, Brazil, Argentina and the United States.

Stock Performance Snapshot

December 21, 2017 – At Thursday’s closing bell, Ituran’s stock advanced 1.76%, ending the trading session at $34.75.

Volume traded for the day: 122.62 thousand shares, which was above the 3-month average volume of 34.54 thousand shares.

Stock performance in the previous six-month period – up 13.01%; past twelve-month period – up 31.63%; and year-to-date – up 31.13%

After yesterday’s close, Ituran’s market cap was at $728.71 million.

Price to Earnings (P/E) ratio was at 17.84.

The stock has a dividend yield of 2.76%.

The stock is part of the Services sector, categorized under the Electronics Wholesale industry. This sector was up 0.4% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 484834

Stock Monitor: Humana Post Earnings Reporting

LONDON, UK / ACCESSWIRE / December 22, 2017 / Active-Investors.com has just released a free report on Kindred Healthcare, Inc. (NYSE: KND) (“Kindred”). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=KND. On December 19, 2017, the Company announced that it has entered into an agreement to be acquired by a Consortium consisting of three companies – private equity firms TPG Capital (“TPG”), Welsh, Carson, Anderson & Stowe (“WCAS”) and health insurer Humana Inc. (NYSE: HUM). The all-cash deal is valued approximately $4.1 billion including debt. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Kindred Healthcare and Humana most recent news is on our radar and our team decided to put out a fantastic report on each company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=KND

www.active-investors.com/registration-sg/?symbol=HUM

Transaction Highlights

As per the terms of the agreement, the Consortium has agreed to pay Kindred’s shareholders $9 in cash for each Kindred’s share they hold. The offer price represents a 27% premium of Kindred’s 90-day volume weighted average price as on December 15, 2017, the last trading day before the rumors about the possible acquisition started doing the rounds. Kindred’s Board of Directors has approved the deal.

Kindred’s operations include home health, hospice, and community care businesses, long-term acute care (LTAC) hospitals, inpatient rehabilitation facilities (IRF), and a contract rehabilitation services business. Post the completion of the transaction, Kindred will be split into two independent companies – Kindred at Home and Kindred Healthcare.

Kindred at Home will have the home health, hospice, and community care businesses. Humana will hold 40% stake in Kindred at Home and the remaining 60% stake will be owned by TPG and WCAS. The agreement has a provision, wherein Humana can acquire the stake of TPG and WCAS in Kindred at Home, via a put/call option in future.

Kindred’s balance businesses including LTAC hospitals, IRFs, and contract rehabilitation services will be operated under Kindred Healthcare and will be fully owned by TPG and WCAS.

The transaction is expected to be completed in the summer of FY 2018 and is subject to regulatory and shareholders’ approvals as well as other closing conditions.

Once the deal is complete, Benjamin A. Breier will be the CEO of the new specialty hospital Company – Kindred Healthcare, while David Causby will be the CEO of the new company – Kindred at Home.

Management Comments

Commenting on the transaction, Benjamin A. Breier, President and CEO of Kindred, said:

“We believe this agreement maximizes value for stockholders and represents a significant step forward in transforming home healthcare in America by enhancing access to care and reducing costs for people living with chronic conditions. In addition, the specialty hospital Company, Kindred Healthcare, will be uniquely positioned to care for the most medically-complex and rehab-intensive populations.”

Bruce D. Broussard, President and CEO of Humana, added:

“Humana is focused on enhancing our capabilities for care in the home to prioritize patient wellness while delivering high-quality care in a low-cost setting. This transaction with Kindred underscores the successful and ongoing execution of our strategy by joining with the most geographically diverse home healthcare provider in the country.”

Jeff Rhodes, Partner at TPG stated:

“We believe this transaction will provide Kindred with additional resources and focus to drive significant value for all stakeholders. We look forward to partnering with Humana, WCAS and the management team at Kindred to build on the complementary capabilities this transaction brings together.”

D. Scott Mackesy, Managing Partner at WCAS, re-joined:

“We have a long history of creative deal-making with corporate partners and look forward to working with Humana, TPG, and Kindred’s management team to deliver the highest quality, most cost-efficient healthcare to all.”

Benefits of the deal for Humana

Kindred management has been looking to sell the Company for nearly over a year. Humana’s investment in Kindred at Home is valued approximately $800 million. Business segments covered under Kindred at Home have over 40,000 caregivers who serve approximately 130,000 patients daily. These segments have annual revenue of approximately $2.5 billion. Humana expects the transaction to be slightly accretive to its diluted EPS from FY19 onwards.

For Humana, this deal is a great way of expanding its footprint in the home healthcare segment. The acquisition is in-line with Humana’s strategy of providing next generation of integrated care delivery to its customers at home in a lower cost setting. The deal will especially benefit Humana’s customers who suffer from chronic ailments.

The deal also expands Humana’s geographic coverage as Kindred’s businesses have a 65% overlap with Humana’s individual Medicare Advantage membership. The deal will enable robust data sharing between Humana and Kindred which will help Humana in improving its offerings in this business segment via improved analytics and predictive modeling. These improvements will lead to increased capabilities and enable better interactions between Humana’s customers and physicians resulting in improved clinical outcomes, ultimately lowering medical costs.

About Kindred Healthcare, Inc.

Louisville, Kentucky-based Kindred is a leading healthcare services Company in the US. Kindred provides various healthcare services through its subsidiaries and has a network which includes 77 long-term acute care hospitals, 19 inpatient rehabilitation hospitals, 16 sub-acute units, 609 home health, hospice and non-medical home care sites of service, 101 inpatient rehabilitation units (hospital-based), and contract rehabilitation service businesses which served 1,653 non-affiliated sites of service.

Kindred provides its services in 2,475 locations across 45 states in US and is supported by approximately 86,400 employees.

About Humana Inc.

Founded in 1961 and headquartered in Louisville, Kentucky, Humana is a leading health insurance and healthcare company committed to helping its medical and specialty members achieve their best health. The Company’s efforts have helped improve the quality of life for people with Medicare, families, individuals, military service personnel, and communities.

About TPG Capital

Founded in 1992, TPG is a leading global alternative asset firm and its investments are across a wide range of asset classes, including private equity, growth venture, real estate, credit, and public equity. TPG aims to build dynamic products and options for its investors while also instituting discipline and operational excellence across the investment strategy and performance of its portfolio. It has office locations across the globe and has over $73 billion of assets under management (AUM).

About Welsh, Carson, Anderson & Stowe (WCAS)

WCAS was formed in 1979 and focuses on investing in two growth industries: healthcare and technology and technology-enabled services in the US. The Firm is currently investing an equity fund, Welsh, Carson, Anderson and Stowe XII, L.P., which closed on over $3.3 billion in commitments. WCAS has a current portfolio of approximately twenty companies with 2017 annual revenues totaling over $16 billion.

Stock Performance Snapshot

December 21, 2017 – At Thursday’s closing bell, Kindred Healthcare’s stock climbed 3.83%, ending the trading session at $9.50.

Volume traded for the day: 6.70 million shares, which was above the 3-month average volume of 1.65 million shares.

Stock performance in the last month – up 21.79%; previous three-month period – up 52.00%; past twelve-month period – up 18.01%; and year-to-date – up 21.02%

After yesterday’s close, Kindred Healthcare’s market cap was at $832.17 million.

The stock has a dividend yield of 5.05%.

The stock is part of the Healthcare sector, categorized under the Long-Term Care Facilities industry. This sector was up 0.1% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 484835

LONDON, UK / ACCESSWIRE / December 22, 2017 / Active-Investors.com has just released a free earnings report on Kinross Gold Corp. (NYSE: KGC) (“Kinross”).If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=KGC . The Company reported its third quarter fiscal 2017 operating results on November 08, 2017. The Gold Miner outperformed top- and bottom-line expectations. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Kinross Gold most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=KGC

Earnings Highlights and Summary

For the quarter ended September 30, 2017, Kinross reported revenues of $828.0 million compared to $910.2 million in Q3 2016. The Company’s revenue numbers topped analysts’ estimates of $796.8 million.

During Q3 2017, Kinross’ revenue from metal sales decreased to $828.0 million compared to $910.2 million during Q3 2016, primarily due to lower gold equivalent ounces sold and lower average realized gold price. The Company’s attributable margin per Au eq. oz. sold was $621 for the reported quarter compared to $617 for Q3 2016.

Kinross’ reported net earnings increased to $60.1 million, or $0.05 per share, for Q3 2017 compared to net earnings of $2.5 million, or $0.00 per share, for Q3 2016, primarily as a result of a non-cash impairment charge recognized in the year-ago same period, and lower production cost of sales.

Kinross’ adjusted net earnings were $84.1 million, or $0.07 per share, for Q3 2017 compared to $128.7 million, or $0.10 per share, for Q3 2016, primarily attributed to a decline in revenue and income tax recovery recognized in the reported quarter. The Company’s earnings beat Wall Street’s estimates of $0.02 per share.

Operating Results

Kinross produced 653,993 attributable Au eq. oz. in Q3 2017 compared to a production of 684,129 attributable Au eq. oz. in Q3 2016.

During Q3 2017, Kinross’ production cost of sales per Au eq. oz. decreased to $662 compared to $719 for Q3 2016, mainly as a result of lower cost of sales per ounce at Round Mountain, Bald Mountain, and Fort Knox. The Company’s production cost of sales per Au oz. on a by-product basis decreased to $645 in the reported quarter versus $695 in the year ago comparable period, based on attributable gold sales of 621,720 ounces, and attributable silver sales of 1,285,860 ounces in Q3 2017.

For Q3 2017, Kinross’ all-in sustaining cost per Au eq. oz. sold decreased to $937 compared to $1,001 in Q3 2016. All-in sustaining cost per Au oz. sold on a by-product basis decreased to $927 in Q3 2017 compared to $987 in Q3 2016. The Company’s average realized gold price in Q3 2017 was $1,283 per ounce compared to $1,336 per ounce in Q3 2016.

Balance Sheet

As of September 30, 2017, Kinross had cash and cash equivalents of $992.1 million compared to $1.06 billion as of June 30, 2017. The Company also had an available credit of $1.51 billion as of September 30, 2017, for a total liquidity of approximately $2.5 billion.

During Q3 2017, Kinross completed a $500.0 million offering of 4.50% debt securities and used the net proceeds, along with cash on hand, to repay its term loan due August 2020. As a result, the Company has no scheduled debt repayments until 2021.

On July 28, 2017, Kinross extended the maturity date of its $1.50 billion revolving credit facility by one year from August 10, 2021, to August 10, 2022.

Kinross’ net operating cash flow was $197.7 million for Q3 2017 compared to $266.2 million for Q3 2016. The Company’s adjusted operating cash flow totaled $320.8 million for the reported quarter compared to $320.3 million for the year-ago corresponding period.

Outlook

Kinross expects to meet its 2017 capital expenditure forecasts of approximately $900 million (+/- 5%). The Company’s other operating costs are now expected to be between $140 million – $150 million for 2017, compared to the previous guidance range of $80 million – $90 million.

Stock Performance Snapshot

December 21, 2017 – At Thursday’s closing bell, Kinross Gold’s stock marginally advanced 0.24%, ending the trading session at $4.24.

Volume traded for the day: 4.92 million shares.

Stock performance in the last twelve-month period – up 42.28%; and year-to-date – up 36.33%

After yesterday’s close, Kinross Gold’s market cap was at $5.29 billion.

Price to Earnings (P/E) ratio was at 48.18.

The stock is part of the Basic Materials sector, categorized under the Gold industry. This sector was up 1.5% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 484836

LONDON, UK / ACCESSWIRE / December 22, 2017 / Active-Investors.com has just released a free research report on MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) (“MabVax”). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=MBVX. On December 20, 2017, MabVax, a clinical-stage biotechnology company that works towards the development of antibody-based products to address unmet medical needs in the treatment of cancer, shared that it has completed the enrollment and initial patient dosing in an expanded cohort of its Phase-1 trial for evaluating MVT-5873 in combination with standard of care chemotherapy in newly diagnosed patients with pancreatic and other CA19-9 positive malignancies. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, MabVax Therapeutics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=MBVX

About MV-5873

MabVax’s antibody MVT-5873 is a fully human IgG1 monoclonal antibody (mAb) that targets sialyl Lewis A (sLea), an epitope on CA19-9. CA19-9 is expressed in more than 90% of pancreatic cancers and in other diseases including small cell lung and GI cancers. It plays an important role in tumor adhesion as well as metastasis, and it is a marker of an aggressive cancer phenotype. In fact, CA19-9 serum levels are known to be a valuable adjunct in the diagnosis, prognosis and treatment monitoring of pancreatic cancer.

At present, MVT-5873 is amidst its Phase-1 clinical trials as a therapeutic agent for patients with pancreatic cancer and other CA19-9 positive tumors.

About the Trial

The second portion of MabVax Phase-1 clinical trial for MV-5873 is an open-label, multi-center nonrandomized dose escalation study that aims to evaluate the safety and maximum tolerated dose and recommended Phase-2 dose of MVT-5873 in combination with a standard of care chemotherapy in subjects with pancreatic and other CA19-9 positive malignancies.

Its secondary objectives comprise evaluation of tumor response rate by RECIST 1.1, duration of response, and determination of pharmacokinetics.

Dr. Eileen O’Reilly, Associate Director of the David M. Rubenstein Center for Pancreatic Cancer Research, attending physician, member at Memorial Sloan Kettering Cancer Center and Professor of Medicine at Weill Cornell Medical College, is serving as the lead investigator in the MVT-5873 Phase-1 clinical trial.

The Company intends to report interim safety and RECIST results from the Phase-1 Trial in the first quarter of 2018.

MVT-5873 Demonstrated Positive Performance, In Combination with Nab-paclitaxel and Gemcitabine

Previously, MabVax had shared an update about MVT-5873 at the AACR-NCI-EORTC International Conference in October 2017. It demonstrated encouraging preliminary tumor response data when MVT-5873 was given in combination with nab-paclitaxel and gemcitabine in newly diagnosed patients with CA19-9 positive pancreatic cancer.

The Company revealed that this combination dose was generally well tolerated in all subjects and that two of three subjects receiving 0.125 mg/kg MVT-5873 in combination with gemcitabine plus nab-paclitaxel had a partial response.

Post that, MabVax decided to expand this cohort to further explore safety and potential response.

And now the Company has declared that it has completed the patient enrollment for the 0.125-mg/kg-expansion cohort.

Stock Performance Snapshot

December 21, 2017 – At Thursday’s closing bell, MabVax’s stock dropped 1.30%, ending the trading session at $0.82.

Volume traded for the day: 60.71 thousand shares.

Stock performance in the last month – up 15.62%; and previous three-month period – up 22.41%

After yesterday’s close, MabVax’s market cap was at $17.12 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.1% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 484837